Introduction
The rapid development of new treatment strategies directed against the varied clinical entities encompassed by the term myelodysplasia calls for new clinical and biologic descriptors. The term 'myelodysplasia' itself refers to a heterogeneous group of clonal hematopoietic disorders characterized by variable clinical features of hematologic insufficiency coupled with morphologic and cytogenetic bone marrow findings. 1, 2 Originally descriptive, diagnostic categories of refractory anemia and preleukemia were classified according to five subtypes based on morphologic criteria of peripheral blood and bone marrow. 3 A specific criterion, dysplasia of the bone marrow, has been described as 'disturbed differentiation of hematopoiesis'. 2 The complex clinical heterogeneity of presentation, the presence or absence of erythropoietin-responsive anemia, neutropenia, and often severe thrombocytopenia were submitted to a classification system dependent on the assessment of blast percentage and abnormal localization of progenitors in the bone marrow with distinct findings in the peripheral blood. More recent classification systems have taken cytopenias and complex cytogenetic findings into consideration when assessing prognostic risk for progression to marrow failure or acute leukemia. 4 A classification system based on marrow topography and blast percentage may never have been satisfactory to describe a complex set of clinical features ranging from megaloblastic hematopoiesis to paraneoplastic autoimmune abnormalities to overt leukemia. 5 A system based on clinical risk assessment may also prove insufficient to identify patients likely to respond to a variety of exciting novel therapies, which may supplant allogeneic or autologous progenitor cell transplantation, treatments limited to a subset of young patients. [6] [7] [8] New agents include differentiation agents, hematopoietins, and hypomethylation agents such as decitabine, and 5 0 -azacytidine. 9-14 Like 5 0 -azacytidine, most clinical trials of active agents demonstrate a consistent response rate across histopathologic categories, thus speaking to the need for a new system to anticipate clinical response in biologically identified groups of patients.
Clinical response identifying distinct disease entities
One of the striking features of recent clinical trials is a response rate within a narrow statistical band for a variety of heterogeneous, and probably pharmacologically distinct treatments. In their article, Silverman and colleagues from the Cancer and Leukemia Group B presented the results of a randomized controlled study of azacitidine administered as a subcutaneous bolus injection for 7 consecutive days every 28 days for four cycles compared to supportive care. 15 In all, 99 eligible patients with refractory anemia, refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEB-T), sideroblastic anemia or chronic myelomonocytic leukemia (CMML) could be assessed for response. Most of these patients (69%) had erythrocyte transfusion-dependent disease, only 7 patients (9%) had high-risk disease. Although bone marrow histology was required within 2 weeks of registration, cytogenetics and molecular phenotyping was not available. Thus, patients with potentially heterogeneous, transfusion-dependent dyshematopoietic disorders were administered an antimetabolite with dose adjustment for hematologic toxicity. Patients were eligible for response assessment after completion of four cycles of treatment. Normalization of all three cell lines was achieved, generally slowly, in 7 patients (7%); 50% or greater improvement in all three cell lines was achieved in another 16 patients (although not all may have had trilineage abnormalities at entry); and a single lineage improvement of 50% or greater, or a decrease in transfusion requirement of 50% or greater, was achieved in 37 patients (37%). The latter category is an important one clinically. Since progression to acute leukemia is not inevitable, a gradual decrease in transfusion-dependent anemia, and a sustained remission of life-threatening granulocytopenia and/or thrombocytopenia may produce significant salutary benefit, even if short of partial or complete remission. Although the treatment could be deemed successful, and not excessively toxic, the median survival for the 99 patients was only 20 months. The disappointing survival statistic was not confined solely to nonresponders; 15% transformed to acute leukemia. The subcutaneous delivery route was associated with results similar to what was achieved by a continuous intravenous infusion schedule.
Azacitidine acts, presumably, by inhibiting DNA methyltransferase, an enzyme in mammalian cells that catalyzes cytidine methylation, thereby influencing gene expression. Although promoted as a hypomethylation agent, the drug could produce an impact by cytotoxicity, and yet the features of response, and even the response statistics, are very similar to what has been achieved with other, often dissimilar agents.
Topotecan is a more typical cytotoxic agent. It interacts with the enzyme topoisomerase I and is believed to promote cell death by stabilizing the complex of the enzyme with DNA. 13 In all, 47 patients with RAEB, RAEB-T, or CMML were treated with the drug given by continuous infusion daily for 5 days every 4-8 weeks up to a maximum of 12 courses. In all, 13 patients (28%) and six patients (13%) achieved complete response and hematologic improvement, respectively. Interestingly, among those with cytogenetic abnormalities in whom complete remission was achieved, the abnormalities resolved. Complete response occurred among patients with all three histologies, with a median duration of 7.5 months. The median survival was 10.5 months. The kinetics of response were not described in the original publication.
Thalidomide, an immuno-modulatory agent with both anticytokine and antiangiogenesis activity, has activity not dissimilar to what has been described for azacitidine. 9, 10 In a study of 83 patients with histologically confirmed myelodysplasia (both lowgrade and intermediate-/high-grade), patients were assigned to receive up to 400 mg of Thalidomide nightly. 9 In all, 51 patients were able to complete 12 weeks of treatment. Of the original 83 patients, 16 achieved hematologic improvement, 11 of whom had what the authors called a major erythroid response, although response did not require resolution of both transfusion requirement and an increase in hemoglobin. As with the azacytidine experience, response was gradual, occurring after 16 or even 20 weeks of therapy. Cytogenetics were available in this study, but no responses were noted despite clinical improvement in responders. Although survival statistics are not available, responding patients had a median duration of response of about 12 months. The activity of thalidomide was confirmed in another study of 34 patients with both low-grade and intermediate-/highgrade myelodysplasia. 10 Again, relatively high doses of thalidomide were administered. Of 29 patients who were evaluable for response, 19 achieved some level of response. Nine patients achieved partial remission as defined by trilineage normalization but with persistence of marrow dysplasia. Hematologic improvement, including transfusion independence, was achieved in another four patients, and six patients showed a significant decrease in erythrocyte transfusion requirement. The median duration of response was 10 months. Only one patient achieved a cytogenetic response. Neither karyotype nor histology predicted response, and again, among responders, response occurred gradually after at least 8 weeks of treatment.
These very different types of treatment produced similar gradual progressive improvement in hematologic parameters, usually without cytogenetic or significant morphologic improvement, over a short observation period, with the duration of response generally about 1 year. Different results were achieved with another distinct single-agent therapy, antithymocyte globulin.
14 In a carefully conducted study, 61 patients with refractory anemia, RAEB, and refractory anemia with ringed sideroblasts, analyzed for morphologic and cytogenetic abnormalities, were treated at the US National Heart, Lung, and Blood Institute with antithymocyte globulin administered intravenously over 4-8 h at a dose of 40 mg/kg daily for 4 days with prednisone. In total, 21 patients (34%) gradually evolved to transfusion independent status, on average 10 weeks after treatment, and were thus deemed responders. Three additional patients became transfusion independent 18 months to 2 years after treatment, although two of them required erythropoietin. Of 21 patients with severe thrombocytopenia, 16 achieved improvement, and some had normalization of platelet count. Similar results were seen with granulocytopenia. Dysplasia of the bone marrow generally remained unchanged, and cytogenetic changes that were identified in four of the responders at presentation also did not change. Response occurred among patients with more favorable histologic subtypes and normal karyotype. Those with high-risk disease had a median survival of 5 months. Unlike the other single-agent treatments previously described, response duration was prolonged. Thus response to antithymocyte globulin may be predicted by the existing histologic and prognostic categories, and may be restricted to a hypocellular disorder of hematopoiesis, itself potentially distinct from typical myelodysplastic syndromes.
Another agent, arsenic trioxide, has been directed against refractory anemia as well as more advanced myelodysplasia. 12, 16 Its potential mechanism of action is again distinct and may involve the induction of apoptosis in the neoplastic clone. Based on its activity in promyelocytic leukemia, arsenic trioxide was effective in vitro in inducing apoptosis in seven of 11 cases of advanced myelodysplasia (AF List et al. Blood 2002; 100: 790; abstract). Little clinical information is available, but in one multicenter trial of arsenic trioxide administered to 32 patients as an intravenous infusion 5 days per week for 2 weeks every month, response was achieved in six of 25 evaluable patients. One CMML patient achieved a partial remission; three other patients had major response in the erythrocyte line, and two others had single-lineage responses in neutrophil and platelet lines. A similar response profile has been achieved using other schedules, and in at least one study by combining the drug with thalidomide (A Raza et al. Blood 2002; 100: 795; abstract). As described with other agents, response could not be predicted by conventional histologic criteria or by prognostic class.
As newer agents are brought into clinical investigation, it seems that the recurring diagnostic criteria identified in the histopathologic classification system will not adequately anticipate response. It may well be that regardless of the class or potential mechanism of action, treatment may initiate a recovery of polyclonal functional hematopoiesis for a distinct subset of patients, or response may itself identify a distinct clinical entity heretofore lost in both the FAB and IPSS systems.
Conclusion
In a time when the only therapies for dysplastic disorders of hematopoiesis included allogeneic transplantation or supportive care, diagnostic categories based on morphology, cytogenetics, and clinical features were important as prognostic tools for predicting progression to hematopoietic failure and/or acute leukemia. In the present era, heterogeneous therapies directed at these clonal disorders seem to produce typical responses characterized by gradual hematopoietic recovery, often in the absence of improvements in the bone marrow or chromosome analysis. These responses, certainly of clinical importance, are not predicted by the current classification system. They appear unexpectedly in 25-50% of patients and are often incomplete, sustained for a period of months to 1 year. It seems that response itself may identify an entity poorly characterized biologically, in which hematopoietic recovery, either oligoclonal or polyclonal, is feasible, regardless of blast percentage or even adverse karyotype. As with other neoplasms, 17 it might be well advised for future myelodysplasia studies to identify, by novel molecular techniques, predictors of response that reflect not only the individual prognosis of patients, but determine whether such a distinct clinical disorder of 'responsive' myelodysplasia does in fact exist.
